Pseudoparkinsonism and secondary suicidal ideation after 3-month paliperidone palmitate administration: a clinical case

被引：0
|
作者：
Fernandes, L. A. C. [1 ]
Serra, L. [2 ]
Lages, M. [1 ]
Almeida, D. [1 ]
Flores, J. [1 ]
Tome, C. [1 ]
Borja-Santos, N. [1 ]
机构：
[1] Hosp Prof Doutor Fernando Fonseca, Psychiat, Lisbon, Portugal
[2] Ctr Hosp Algarve, Psychiat, Faro, Portugal
来源：
EUROPEAN PSYCHIATRY | 2019年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
E-PV0712
引用
收藏
页码：S474 / S475
页数：2
相关论文
共 50 条
  • [1] Use of paliperidone palmitate 3-month formulation in clinical practice: an extended study
    Romero Guillena, S. L.
    Plasencia Garcia de Diego, B. O.
    Gotor Sanchez-luengo, F.
    Garcia Salguero, M.
    [J]. EUROPEAN PSYCHIATRY, 2019, 56 : S264 - S264
  • [2] Use of paliperidone palmitate 3-month formulation: Effectiveness and functionality in clinical practice
    Romero Guillena, S. L.
    Navarro, R.
    Garcia de Diego, B. O. Plasencia
    Santamaria, O.
    Gotor Sanchez-Luengo, F.
    [J]. EUROPEAN PSYCHIATRY, 2018, 48 : S197 - S197
  • [3] The current data on the 3-month paliperidone palmitate formulation for the treatment of schizophrenia
    Bioque, Miquel
    Bernardo, Miquel
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (14) : 1623 - 1629
  • [4] COMPARISON OF PALIPERIDONE PALMITATE 3-MONTH AND PALIPERIDONE PALMITATE 1-MONTH FORMULATION FOR NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: A PHASE 3 NON-INFERIORITY STUDY
    Mathews, Maju
    Gopal, Srihari
    Singh, Arun
    Gogate, Jagadish
    Kim, Edward
    Pungor, Katalin
    [J]. SCHIZOPHRENIA BULLETIN, 2018, 44 : S311 - S311
  • [5] Paliperidone palmitate 3-month formulation and sexual dysfunction in young schizophrenic patients
    Plasencia Garcia De Diego, B. O.
    Romero Guillena, S. L.
    Gotor Sanchez-Luengo, F.
    [J]. EUROPEAN PSYCHIATRY, 2019, 56 : S261 - S261
  • [6] Paliperidone Palmitate 3-Month Dosing in Special Patient Populations and Derivation of Secondary Pharmacokinetic Parameters Based on Simulations
    Samtani, Mahesh N.
    Rossenu, Stefaan
    Vermeulen, An
    Russu, Alberto
    [J]. BIOLOGICAL PSYCHIATRY, 2016, 79 (09) : 353S - 353S
  • [7] Healthcare resource use of paliperidone palmitate 3-month injection vs. paliperidone palmitate 1-month injection: An analysis of phase III clinical trial hospital data
    Woodruff, K.
    Chirila, C.
    Zheng, Q.
    Van Impe, K.
    Nuamah, I.
    [J]. EUROPEAN PSYCHIATRY, 2016, 33 : S265 - S266
  • [8] Symptomatic and functional remission in European patients with schizophrenia after paliperidone palmitate treatment (1-month and 3-month formulations)
    Savitz, A.
    Xu, H.
    Gopal, S.
    Nuamah, I.
    Hough, D.
    Hargarter, L.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S546 - S547
  • [9] Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
    Nash, Abigail, I
    Turkoz, Ibrahim
    Savitz, Adam J.
    Mathews, Maju
    Kim, Edward
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2019, 15 : 731 - 737
  • [10] Population Pharmacokinetic/Pharmacodynamic Modeling of Paliperidone Palmitate 3-Month Formulation in Asian Population
    Russu, Alberto
    Mathews, Maju
    Savitz, Adam
    Gopal, Srihari
    Feng, Yu
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 242 - 242
12345